Iron and Parkinson’s
This article was originally published in The Tan Sheet
Executive Summary
Researcher Cathy Levenson says she would be "nervous about just handing someone iron supplements and saying 'have at it,'" following results of a study showing too much iron can increase the risk of developing Parkinson's disease. Levenson's study, published in the October Experimental Neurology, showed lower levels of iron delayed Parkinson's in at-risk mice and slowed Parkinson's progression in already infected mice, but that too little of the mineral could promote the disease by causing shortages in dopamine, a neurotransmitter responsible for balance control and movement. Levenson, Florida State University, Tallahassee, et al., recommend consumers obtain iron from natural food sources rather than supplementation to avoid an excessive amount of the mineral...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.